Skip to main content
SpringerLink
Log in

Etanercept Therapy for Psoriasis in a Patient with Active Pulmonary Tuberculosis

  • Case Report
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Anti-tumor necrosis factor alpha agents are effective treatments for psoriasis. However, the use of these agents is associatedwith an increased risk of tuberculosis reactivation. An algorithmic approach to screening for latent tuberculosis infection has been recommended tominimize the risk of tuberculosis reactivation. However, clinical suspicion should override the results of screening tests. This report describes the case of a 49-year-old man who experienced reactivation of latent tuberculosis during treatment with etanercept, despite a negative tuberculin skin test and chest radiograph showing no abnormalities before the commencement of etanercept therapy; this patient was able to receive further treatment with etanercept following treatment for tuberculosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209–17

    Article  PubMed  Google Scholar 

  2. Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON®–TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR 2005; 54 (No. RR-15): 49–55

    Google Scholar 

  3. Desai N, Raste Y, Cooke NT, et al. QuantiFERON–TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy. Br J Dermatol 2008; 158: 1137–8

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Stephanie Blick of inScience Communications who provided assistance with English-language editing. This assistance was funded by Pfizer. Dr Huo reports no conflicts of interest. Dr Romanelli received honoraria from Amgen for being a speaker on their behalf and was granted an Amgen fellowship in 2008.

Author information

Authors and Affiliations

  1. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA

    Ran Huo &  Paolo Romanelli

Authors
  1. Ran Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Romanelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Romanelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huo, R., Romanelli, P. Etanercept Therapy for Psoriasis in a Patient with Active Pulmonary Tuberculosis. AM J Clin Dermatol 11 (Suppl 1), 39–40 (2010). https://doi.org/10.2165/1153421-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1153421-S0-000000000-00000

Keywords

Search

Navigation